Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

RSS Feed

Home
/
Brands
/
BF Suma Pharmaceuticals, Inc.

BF Suma Pharmaceuticals, Inc. Recalls

All product recalls associated with BF Suma Pharmaceuticals, Inc..

Get alerts for this brand

Recall Summary

Total Recalls

1000

Past Year

304

Class I (Serious)

Most Recent

Nov 2025

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 461–480 of 4747 recalls

Xlim Express Coffee (Longreen) – Undeclared Allergens (2024)

Undeclared Allergen

Undeclared allergens due to sub-ingredients, soy lecithin and coconut oil

Class IIModerate

FDAApr 18, 2024CA, TX• BF Suma Pharmaceuticals, Inc.

Reishi Coffee (Longreen) – Undeclared Allergens (2024)

Undeclared Allergen

Undeclared allergens due to sub-ingredients, soy lecithin and coconut oil

Class IIModerate

FDAApr 18, 2024CA, TX• BF Suma Pharmaceuticals, Inc.

Diltiazem Hydrochloride (Glenmark) – Dissolution Failure (2024)

Failed Dissolution Specifications

1...22 232425 26...238

Page 24 of 238Next

Class II

Moderate

FDAApr 17, 2024Nationwide• Glenmark Pharmaceuticals Inc., USA

Abilify 15mg Tablets (Otsuka) – Product Contamination (2024)

Cross Contamination with Other Products

Class IIILow

FDAApr 9, 2024Nationwide• Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.

Abilify 30mg Tablets (Otsuka) – Product Contamination (2024)

Cross Contamination with Other Products

Class IIILow

FDAApr 9, 2024Nationwide• Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.

Abilify 5mg Tablets (Otsuka) – Product Contamination (2024)

Cross Contamination with Other Products

Class IIILow

FDAApr 9, 2024Nationwide• Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.

Abilify 10mg Tablets (Otsuka) – Product Contamination (2024)

Cross Contamination with Other Products

Class IIILow

FDAApr 9, 2024Nationwide• Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.

Mainstays Electric Mini Choppers – Laceration Risk (2024)

Laceration Risk

This recall involves Mainstays Electric Mini Choppers with model number MS14100094536S1. The choppers are rechargeable and cordless, and have a green lid, white body, and clear plastic bowl. They have one blade attachment, which consists of three curved blades on one white plastic spindle. Model number MS14100094536S1 is on the label attached to the bottom of the clear plastic bowl.

CPSCApr 4, 2024Nationwide• Shuangma Plastic Manufacturing Inc., of China

Cyclophosphamide 1g Injection (X-Gen) – Labeling Error (2024)

Labeling: Incorrect or missing Package Insert: There is an error on the Package Insert (PI), section 2.3, Preparation, Handling, and Administration. The concentration of the reconstituted product is listed as '20 mg per vial.' This information should read: '20 mg per mL'.

Class IIILow

FDAApr 2, 2024Nationwide• X-Gen Pharmaceuticals Inc.

Cyclophosphamide 500mg Injection (X-Gen) – Labeling Error (2024)

Class IIILow

FDAApr 2, 2024Nationwide• X-Gen Pharmaceuticals Inc.

Isotretinoin 40mg Capsules (Teva) – Superpotent Drug (2024)

Superpotent Drug: The 3-month stability result for assay was found to be above specification limit

Class IIModerate

FDAMar 28, 2024Nationwide• Teva Pharmaceuticals USA, Inc

Diltiazem Extended-Release Capsules (Glenmark) – Dissolution Failure (2024)

Failed Dissolution Specifications: Out of Specification (OOS) was reported in test of dissolution at the 12th month time point in long term stability study.

Class IIModerate

FDAMar 26, 2024Nationwide• Glenmark Pharmaceuticals Inc., USA

Methylergonovine Tablets (Amneal) – Dissolution Failure (2024)

Failed Dissolution Specifications

Class IIModerate

FDAMar 25, 2024Nationwide• Amneal Pharmaceuticals of New York, LLC

Rifampin Capsules (Lupin) – Subpotent Medication (2024)

Subpotent Drug

Class IIModerate

FDAMar 21, 2024Nationwide• Lupin Pharmaceuticals Inc.

VCF Contraceptive Film (Apothecus) – Manufacturing Deviation (2024)

cGMP Diviations

Class IIModerate

FDAMar 21, 2024Nationwide• Apothecus Pharmaceutical Corp.

Vancomycin Oral Solution (Amneal) – Superpotent Dosage (2024)

Superpotent Drug: Due to overfilling of drug powder

Class IHigh

FDAMar 21, 2024Nationwide• Amneal Pharmaceuticals of New York, LLC

Atellica CH Iron3 (Siemens) – Test Result Inaccuracy (2024)

Potential for falsely elevated Chol_2, LDLC, and Trig_2 results on the Atellica CH and Atellica CI analyzers when the previous result in the cuvette was Iron3. Results in a positive bias ranging from 2-16% -impacts calibrator, quality control (QC), and patient results.

FDAMar 13, 2024Nationwide• Siemens Healthcare Diagnostics, Inc.